Novo Nordisk’s weight loss injection, Wegovy, could potentially thwart 1.5 million heart attacks and strokes over 10 years, according to a recent study, reports CNBC.
Researchers from the University of California, Irvine discovered that Wegovy could also result in 43 million fewer Americans with obesity over the same timeframe. The study was partially financed by Novo Nordisk.
The results of the research support the initial data from the Danish company’s recent clinical trial, which found that Wegovy reduced the risk of serious heart issues and heart-related death by 20%.
These findings suggest that Wegovy, Ozempic and other similar obesity drugs could provide significant health benefits beyond just being ‘miracle’ weight loss drugs. This could potentially exert more pressure on insurers to cover obesity medications, which currently cost more than $1,000 per month.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.